17/05/2024  15:38:39 Var. +0.20 Volume Denaro- Lettera- Capitalizzazione di mercato Dividend Y. Rapporto P/E
37.30EUR +0.54% 3,973
Fatturato: 147,570.93
-Quantità in denaro: - -Quantità in lettera: - 2.01 bill.EUR 2.36% 32.11

Descrizione business

Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company’s integrated business model comprises inhouse development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm holds approximately 900 marketing authorizations (Arzneimittelzulassungen) for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company’s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm’s business model also includes a parallel import business, which operates under the “axicorp” brand.
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Dr. Hans-Georg Feldmeier
Consiglio di amministrazione
Dr. Andreas Eberhorn, Christof Dreibholz
Consiglio di sorveglianza
Wilhelm Beier, Dr. Erwin Kern, Lothar Lanz
 

Dati aziendali

Name: Dermapharm Holding SE
Indirizzo: Lil-Dagover-Ring 7,D-82031 Grünwald
Telefono: +49-89-64186-0
Fax: +49-89-64186-130
E-mail: -
Internet: ir.dermapharm.de/index.php
Industria: Healthcare
Settore: Pharmaceutical Industry
Sub settore: Pharmaceuticals
Fine dell'anno finanziario: 31/12
Flottante libero: -
Data dell'IPO: 09/02/2018

Rapporti con gli investitori

Name: Britta Hamberger
IR telefono: +49-89-64186-233
IR Fax: +49-89-64186-165
IR e-mail: ir@dermapharm.com

Company calendar

CW 23 | 06/06/2024 Ex-Dividend
CW 23 | 07/06/2024 Record Date
CW 24 | 10/06/2024 Dividend Payment
CW 26 | 27/06/2024 General Shareholder Meeting
CW 35 | 27/08/2024 Interim Report 2nd Quarter/6 Months
 

Principali azionisti

Themis Beteiligungs-AG
 
68.50%
free float
 
31.50%